Two products from Pfizer – the investigational PARP inhibitor, talazoparib, for metastatic breast cancer and a novel non-steroidal eczema ointment, crisaborole – are among the 14 new entries to the list of products that the European Medicines Agency is reviewing for potential authorization across the EU.
Other new additions to the list, which the EMA compiled on June 6, include Mitsubishi Tanabe Pharma’s edaravone for...








